High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The purpose of the study is to investigate the efficacy of combined treatment with temozolomide (TMZ) and metformin for glioblastoma (GBM) in vitro and in vivo. Materials and Methods We investigated the efficacy of combined treatment with TMZ and metformin using cell viability and apoptosis assays. A GBM orthotopic mice model was established by inoculation of 5105 U87 cells and treated with metformin, TMZ, and the combination for 4 weeks. Western blotting and immunofluorescence of tumor specimens were analyzed to investigate AMPactivated protein kinase (AMPK) and AKT pathway. Results The combination of TMZ and metformin showed higher cytotoxicity than single agents in U87, U251, and A172 cell lines. A combination of high-dose metformin and TMZ showed the highest apoptotic activity. The combination of TMZ and metformin enhanced AMPK phosphorylation and inhibited mammalian target of rapamycin phosphorylation, AKT phosphorylation, and p53 expression. The median survival of each group was 43.6, 55.2, 53.2, 65.2, and 71.3 days for control, metformin treatment (2 mg/25 g/day or 10 mg/25 g/day), TMZ treatment (15 mg/kg/day), combination treatment with low-dose metformin and TMZ, and combination treatment with high-dose metformin and TMZ, respectively. Expression of fatty acid synthase (FASN) was significantly decreased in tumor specimens treated with metformin and TMZ. Conclusion The combination of metformin and TMZ was superior to monotherapy using metformin or TMZ in terms of cell viability in vitro and survival in vivo. The combination of high-dose metformin and TMZ inhibited FASN expression in an orthotopic model. Inhibition of FASN might be a potential therapeutic target of GBM.
Abstract
Purpose The purpose of the study is to investigate the efficacy of combined treatment with temozolomide (TMZ) and metformin for glioblastoma (GBM) in vitro and in vivo. Materials and Methods We investigated the efficacy of combined treatment with TMZ and metformin using cell viability and apoptosis assays. A GBM orthotopic mice model was established by inoculation of 5105 U87 cells and treated with metformin, TMZ, and the combination for 4 weeks. Western blotting and immunofluorescence of tumor specimens were analyzed to investigate AMPactivated protein kinase (AMPK) and AKT pathway. Results The combination of TMZ and metformin showed higher cytotoxicity than single agents in U87, U251, and A172 cell lines. A combination of high-dose metformin and TMZ showed the highest apoptotic activity. The combination of TMZ and metformin enhanced AMPK phosphorylation and inhibited mammalian target of rapamycin phosphorylation, AKT phosphorylation, and p53 expression. The median survival of each group was 43.6, 55.2, 53.2, 65.2, and 71.3 days for control, metformin treatment (2 mg/25 g/day or 10 mg/25 g/day), TMZ treatment (15 mg/kg/day), combination treatment with low-dose metformin and TMZ, and combination treatment with high-dose metformin and TMZ, respectively. Expression of fatty acid synthase (FASN) was significantly decreased in tumor specimens treated with metformin and TMZ. Conclusion The combination of metformin and TMZ was superior to monotherapy using metformin or TMZ in terms of cell viability in vitro and survival in vivo. The combination of high-dose metformin and TMZ inhibited FASN expression in an orthotopic model. Inhibition of FASN might be a potential therapeutic target of GBM.
참고문헌 (24)
- Kyritsis AP, "An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting", Cancer Chemother Pharmacol, 67, pp.971~983 (2011)
- Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma", N Engl J Med, 352, pp.987~996 (2005)
- Di Cristofori A, "Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma", Anticancer Res, 33, pp.3383~3389 (2013)
- Zustovich F, "Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study", Anticancer Res, 33, pp.3487~3494 (2013)
- Saran F, "Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy", Neuro Oncol, 18, pp.991~1001 (2016)
- Hirsch HA, "Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission", Cancer Res, 69, pp.7507~7511 (2009)
- Gou S, "Low concentrations of metformin selectively inhibit CD133(+) cell proliferation in pancreatic cancer and have anticancer action", PLoS One, 8, pp.e63969~ (2013)
- Nangia-Makker P, "Metformin: a potential therapeutic agent for recurrent colon cancer", PLoS One, 9, pp.e84369~ (2014)
- Shank JJ, "Metformin targets ovarian cancer stem cells in vitro and in vivo", Gynecol Oncol, 127, pp.390~397 (2012)
- Yu Z, "Temozolomide in combination with metformin act synergistically to inhibit proliferation and expansion of glioma stem-like cells", Oncol Lett, 11, pp.2792~2800 (2016)
- Yu Z, "Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo", Oncotarget, 6, pp.32930~32943 (2015)
- Sesen J, "Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response", PLoS One, 10, pp.e0123721~ (2015)
- Bosi E, "Metformin: the gold standard in type 2 diabetes: what does the evidence tell us?", Diabetes Obes Metab, 11(Suppl 2), pp.3~8 (2009)
- Cerezo M, "Metformin blocks melanoma invasion and metastasis development in AMPK", p53-dependent manner, 2013, pp.12, 1605~1615
- Nair AB, "A simple practice guide for dose conversion between animals and human", J Basic Clin Pharm, 7, pp.27~31 (2016)
- Kordes S, "Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial", Lancet Oncol, 16, pp.839~847 (2015)
- Wakil SJ, "Fatty acid synthase, a proficient multifunctional enzyme", Biochemistry, 28, pp.4523~4530 (1989)
- Seguin F, "The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16- F10 melanomas", Br J Cancer, 107, pp.977~987 (2012)
- Zaytseva YY, "Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer", Cancer Res, 72, pp.1504~1517 (2012)
- Menendez JA, "Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis", Nat Rev Cancer, 7, pp.763~777 (2007)
- Grube S, "Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis", J Neurooncol, 118, pp.277~287 (2014)
- Zhou Y, "Inhibition of fatty acid synthase suppresses neovascularization via regulating the expression of VEGF-A in glioma", J Cancer Res Clin Oncol, 142, pp.2447~2459 (2016)
- Yasumoto Y, "Inhibition of fatty acid synthase decreases expression of stemness markers in glioma stem cells", PLoS One, 11, pp.e0147717~ (2016)
- Yang SH, "Metformin treatment reduces temozolomide resistance of glioblastoma cells", Oncotarget, 7, pp.78787~78803 (2016)